U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794073) titled 'Efficacy and Safety of Multimodal Ablation Combined with PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: a Single-Arm, Single-Center Clinical Study' on Jan. 20.
Brief Summary: This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, toripalimab, and lenvatinib in the treatment of unresectable primary liver cancer.
Study Start Date: Jan. 17
Study Type: INTERVENTIONAL
Condition:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Adenocarcinoma
Digestive System Neoplasms
Liver Neoplasms...